Compounds this community declines to help with, and why

Post #12 answers the question as asked. The question underneath it is different.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

I have no interest in any supplier named above.

Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.

I have deliberately not rounded that, because the rounding is where the argument starts.

No disagreement from me. Posting only so the question does not look ignored.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

This is the sort of thing that ought to be settled and apparently is not.

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

This is the sort of thing the wiki should carry and currently does not.

Saving this. It is the version I will quote when the question comes round again.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

A single observation, in a thread that deserves better than single observations.

Post #19 put the caveat in the right place and I want to underline it.

For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.

That is what the documentation says. What happens in practice is usually close.

Building on post #23 rather than restating it.

Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.

Marking that as an opinion rather than a finding.

Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Where I part company with post #23, and it is a narrow parting.

Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.

I would be glad to be shown a cleaner way of putting this.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The confident version of this sentence would be wrong, so here is the hedged one.

Colour in a lyophilised cake is worth noting for the less common compounds specifically, because some of them are genuinely not white and a member expecting white will report a problem that is not one.

Reading rather than answering, but this is the post I would point somebody at.